Welcome to our dedicated page for Bausch + Lomb Corporation SEC filings (Ticker: BLCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bausch + Lomb Corporation (BLCO) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, drawn directly from the EDGAR system. As a Canadian-incorporated issuer with common shares listed on the New York Stock Exchange and the Toronto Stock Exchange, Bausch + Lomb files annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, along with exhibits such as credit agreements, indentures and press releases.
For an eye health company operating in vision care, surgical products and ophthalmic pharmaceuticals, these filings contain detailed information on segment performance, risk factors, capital structure and governance. Recent Form 8-K filings describe material events including secured notes offerings, amendments to the company’s credit and guaranty agreement, creation of new term loan tranches and revolving credit facilities, refinancing of existing borrowings, quarterly financial results, investor day materials and changes in the composition of the board of directors.
Investors can use this page to review Bausch + Lomb’s disclosures on direct financial obligations, covenants, leverage ratios and maturity profiles, as well as governance items such as director appointments, committee assignments and executive compensation arrangements referenced in current reports. Over time, the archive will also include annual 10-K reports and quarterly 10-Q reports, which provide more comprehensive discussions of the company’s business, segments, risk factors and financial statements.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the nature of new term loans, secured notes, amendments, results of operations and other reported events. Users can also monitor current reports that reference press releases on topics such as investor day presentations, refinancing transactions and quarterly earnings, using this page as a central source for BLCO’s regulatory history and ongoing disclosure record.
Bausch + Lomb announced significant debt refinancing activities on June 18, 2025. The company has priced an offering of €675 million senior secured floating rate notes due 2031, increased from the initially announced €600 million. The notes will be sold at 99.500% of principal value.
The company is also pursuing a refinancing package including a $2.325 billion new term B loan facility (increased from $2.2 billion) with Term SOFR + 4.25% interest rate, and a $800 million new revolving credit facility. These proceeds will be used to:
- Repay outstanding borrowings under existing revolving credit facility
- Refinance term A loans due 2027
- Refinance term B loans due 2027
- Pay related fees and expenses
The notes offering is expected to close on June 26, 2025, subject to customary conditions. The notes will be offered to qualified institutional buyers in the US under Rule 144A and internationally under Regulation S, with first-priority liens on assets securing the company's credit agreement.